The use of Bisphenol A (BPA) has widely been replaced in consumer products by analogs BPB, BPE, BPF, BPS, and BPAF. Recent studies have linked these substitutes to similar adverse health outcomes as BPA, including disruption of endocrine pathways in animal and human studies. We designed a novel MS method, developed specifically for this study, to capture the most relevant BPA alternatives, BPB, BPE, BPF, BPS, BPAF and 4-NP in human blood and urine to quantify potential in utero exposures. To our knowledge, this is the first study to explore in utero exposure to these BPA analogs and the first U.S. study to test for BPA in maternal/fetal pairs. The method was run on 30 paired maternal urine and fetal cord blood samples from mothers undergoing elective Caesarean sections. 90% of mothers and 77% of babies tested positive for at least one BP analog. 83% of mothers tested positive for BPAF, 60% for BPS, 57% for BPB, 17% for BPF and 7% for BPA. 57% of babies tested positive for BPAF and 50% for BPF. BPA and BPB were detected in one cord blood sample each. BPS was not detected in cord blood. BPE was not detected in any fetal cord blood or maternal urine samples. These findings demonstrate the pervasiveness of some BP analogs in pregnant women and their babies at birth.

在消费产品中，双酚A（BPA）的使用已被类似物BPB，BPE，BPF，BPS和BPAF广泛取代。最近的研究已经将这些替代品与BPA相似的不利健康结果联系起来，包括在动物和人体研究中破坏了内分泌途径。我们设计了一种专门为此研究开发的新型MS方法，以捕获人血和尿液中最相关的BPA替代品，BPB，BPE，BPF，BPS，BPAF和4-NP，以量化子宫暴露的潜力。据我们所知，这是首次在子宫内探索这些BPA类似物暴露的研究，也是美国首个测试母婴对BPA的研究。该方法对30例行选择性剖腹产的母亲产妇的尿液和胎儿脐带血样本进行了分析。90％的母亲和77％的婴儿的至少一种BP类似物测试呈阳性。83％的母亲BPAF呈阳性，BPS为60％，BPB为57％，BPF为17％，BPA为7％。57％的婴儿的BPAF和BPF呈阳性。每个脐带血样本中均检测到BPA和BPB。在脐带血中未检测到BPS。在任何胎儿脐带血或孕妇尿液样本中均未检测到BPE。这些发现证明了某些BP类似物在孕妇及其婴儿出生时的普遍性。